Sugi Predict

Sugi Predict / Compounds / SCHEMBL724387

SCHEMBL724387

SCHEMBL724387

N[C@@H](Cc1cnc[nH]1)C(=O)OC(=O)CCC(=O)OC(=O)[C@@H](N)Cc1cnc[nH]1

nearest known ligand 0.63

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 1/20 0.63
▸ SLC7A5 Q01650 1/20 0.63
▸ HRH4 Q9H3N8 3/20 0.49
▸ HRH3 Q9Y5N1 3/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ GLA P06280 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ NFKB1 P19838 1/20 0.49
▸ THPO P40225 1/20 0.49
▸ LMNA P02545 1/20 0.47
▸ APEX1 P27695 1/20 0.47
▸ BLM P54132 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21772061 0.95 CYP3A4 (0.61) CYP3A4SLC7A5HRH4HRH3ALDH1A1
SCHEMBL22462183 0.94 CYP3A4 (0.60) CYP3A4SLC7A5HRH4HRH3ALDH1A1
SCHEMBL22462180 0.94 CYP3A4 (0.60) CYP3A4SLC7A5HRH4HRH3ALDH1A1
SCHEMBL5268405 0.92 CYP3A4 (0.57) CYP3A4SLC7A5HRH4HRH3ALDH1A1
SCHEMBL1537285 0.91 CYP3A4 (0.71) CYP3A4SLC7A5HRH4HRH3ALDH1A1
SCHEMBL163444 0.91 CYP3A4 (0.71) CYP3A4SLC7A5HRH4HRH3ALDH1A1
SCHEMBL23756736 0.90 CYP3A4 (0.61) CYP3A4SLC7A5HRH4HRH3ALDH1A1
SCHEMBL23756950 0.90 CYP3A4 (0.61) CYP3A4SLC7A5HRH4HRH3ALDH1A1
SCHEMBL1537316 0.90 CYP3A4 (0.61) CYP3A4SLC7A5HRH4HRH3ALDH1A1
SCHEMBL4356755 0.90 CYP3A4 (0.66) CYP3A4SLC7A5HRH4HRH3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12576124-B2 Formulation of a conjugate of a tubulysin analog to a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD (CN) 2026-03-17 — — US claimed
WO-2025036449-A1 PHARMACEUTICAL COMPOSITION CONTAINING IMMUNOCONJUGATE AND USE THEREOF 上海迈晋生物医药科技有限公司 2025-02-20 — — WO claimed
CN-110494453-B Anti-tryptase antibodies, compositions thereof and uses thereof 豪夫迈·罗氏有限公司 2023-05-26 — — CN claimed
US-20220249594-A1 A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE HANGZHOU DAC BIOTECH CO., LTD (CN) 2022-08-11 — — US claimed
CN-114040781-A Formulation of conjugate of TUBULYSIN derivative and cell binding molecule 杭州多禧生物科技有限公司 2022-02-11 — — CN claimed
WO-2018148585-A1 ANTI-TRYPTASE ANTIBODIES, COMPOSITIONS THEREOF, AND USES THEREOF GENENTECH, INC. (US) 2018-08-16 — — WO claimed
US-20180000932-A1 FORMULATION OF AGLYCOSYLATED THERAPEUTIC ANTIBODIES NOVELMED THERAPEUTICS INC (US) 2018-01-04 — — US claimed
EP-3240571-A1 FORMULATION OF AGLYCOSYLATED THERAPEUTIC ANTIBODIES NovelMed Therapeutics, Inc. (US) 2017-11-08 — — EP claimed
WO-2016109822-A1 FORMULATION OF AGLYCOSYLATED THERAPEUTIC ANTIBODIES NOVELMED THERAPEUTICS, INC. (US) 2016-07-07 — — WO claimed
US-8318161-B2 Anti-oxidized LDL antibody formulation GENENTECH, INC. (US) 2012-11-27 — — US claimed
EP-2403874-A1 ANTIBODY FORMULATION Genentech, Inc. (US) 2012-01-11 — — EP claimed
US-20100239567-A1 Antibody Formulation GENENTECH, INC. (US) 2010-09-23 — — US claimed
WO-2010102241-A1 ANTIBODY FORMULATION GENENTECH, INC. (US) 2010-09-10 — — WO claimed
US-20260144889-A1 CEACAM5 ANTIBODY-DRUG CONJUGATE FORMULATION SANOFI (FR) 2026-05-28 — — US disclosed
US-20260091081-A1 A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE HANGZHOU DAC BIOTECH CO., LTD (CN) 2026-04-02 — — US disclosed
US-12576124-B2 Formulation of a conjugate of a tubulysin analog to a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD (CN) 2026-03-17 — — US disclosed
WO-2010045344-A1 COMBINATION THERAPY COMPRISING A C-MET ANTAGONIST AND A VEGF ANTAGONIST GENENTECH, INC. (US) 2010-04-22 — — WO disclosed
WO-2009111691-A2 COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS GENENTECH, INC. (US) 2009-09-11 — — WO disclosed
US-20090226443-A1 COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS GENENTECH, INC. (US) 2009-09-10 — — US disclosed
WO-2009100645-A1 POLYCATIONIC GENE CARRIERS FORMED OF ENDOGENOUS AMINO GROUP-BEARING MONOMERS JIN TUO (CN) 2009-08-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12576124-B2 Formulation of a conjugate of a tubulysin analog to a cell-binding molecule CD4, TAP1, MCTS1 CYP3A4 4877/4885SLC7A5 157/4885HRH4 1743/4885
US-20260144889-A1 CEACAM5 ANTIBODY-DRUG CONJUGATE FORMULATION EPCAM, CD44, MUC1 CYP3A4 2286/4885SLC7A5 211/4885HRH4 438/4885
US-20090226443-A1 COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS MET, EGFR, ERBB2 CYP3A4 3532/4885SLC7A5 2071/4885HRH4 1161/4885
US-20260091081-A1 A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE CD4, MALT1, LY6K CYP3A4 4708/4885SLC7A5 268/4885HRH4 1203/4885
US-20220249594-A1 A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE CD4, TEKT1, NTSR1 CYP3A4 4774/4885SLC7A5 1110/4885HRH4 1380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.